<DOC>
	<DOCNO>NCT02966028</DOCNO>
	<brief_summary>The primary objective ass effect 2 dose level SNF472 ( 300 mg 600 mg ) compare placebo progression absolute change coronary artery calcium volume score 12‑month ( 52 week ) period ESRD patient HD</brief_summary>
	<brief_title>Effect SNF472 Progression Cardiovascular Calicification End-Stage-Renal-Disease ( ESRD ) Patients Hemodialysis ( HD )</brief_title>
	<detailed_description>Reducing progression cardiovascular calcification ( CVC ) HD patient may improve severe burden CV disease relate underlying ESRD . As therapy currently indicate target CVC , need investigate ability SNF472 reduce CVC progression , ultimately , improve CV outcome HD patient . This phase 2b double-blind , randomise , placebo-controlled study design assess effect SNF472 progression CVC measure calcium volume CAC/Agatston score ESRD patient receive HD . The study hypothesis administration SNF472 52 week slow progression CVC patient population compare placebo .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<criteria>Female male patient , 18 80 year ( inclusive ) age randomisation CAC score 100 2000 AU ( Agatston Units ) inclusive within 3week period prior randomisation measure multidetector CT scanner Patients EITHER ≥ 55 year OR history diabetes mellitus randomisation Patients HD ≥ 6 month prior randomisation Willing able understand sign inform consent Scheduled date kidney transplant know live donor Weight 300 lb ( 136 kg ) Hospitalisation previous 3 month prior randomisation unstable angina , MI , stroke , transient ischaemic attack , amputation peripheral coronary bypass surgery History unstable heart failure previous 3 month , define unplanned presentation hospital dialysis treatment facility signs/symptoms acute pulmonary edema require ultrafiltration therapy History cancer remission &lt; 5 year prior randomisation . A history basal cell carcinoma Stage 1 squamous cell carcinoma skin allow Pregnant try become pregnant , currently breastfeed , childbearing potential ( include perimenopausal woman menstrual period within one year ) willing practice birth control use double barrier method ( criterion apply woman ) least 30 day post last dose study medication Hypocalcaemia define serum calcium 8.0 mg/dL ( 2.0 mmol/L ) serum calcium proximal screen per patient 's medical record Extreme elevation serum phosphorous , define serum phosphorous 10 mg/dL ( 3.23 mmol/L ) within last 2 month proximal screen per patient 's medical record Uncontrolled hypertension define 2 consecutive postdialysis diastolic blood pressure ( DBP ) &gt; 100 mmHg within last 2 month proximal screen expect survival &lt; 2 year Investigator 's medical opinion Known active drug alcohol abuse within 1 year randomisation Use investigational drug within 30 day randomisation Noncompliance dialysis treatment , opinion Investigator , evidence either repeat missed dialysis treatment significant noncompliance patient 's medication regimen Inability comply require study procedure schedule , inability speak read protocolderived language patient 's clinical site , unwillingness inability give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CAC</keyword>
	<keyword>calcium</keyword>
	<keyword>ESRD</keyword>
	<keyword>calcification</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>heart</keyword>
	<keyword>kidney</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>Agatston</keyword>
</DOC>